Skip to main content
Erschienen in: Journal of Gastroenterology 4/2021

04.02.2021 | Original Article—Alimentary Tract

Achalasia and esophageal cancer: a large database analysis in Japan

verfasst von: Hiroki Sato, Shuji Terai, Yuto Shimamura, Shinwa Tanaka, Hironari Shiwaku, Hitomi Minami, Chiaki Sato, Ryo Ogawa, Hiroshi Yokomichi, Haruhiro Inoue

Erschienen in: Journal of Gastroenterology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Achalasia has been reported to be associated with esophageal cancers (ECs). However, owing to the rarity of achalasia, details of achalasia-related ECs are not well investigated.

Method

The incidence of ECs in Japanese patients with achalasia and achalasia-related esophageal motility disorders (EMDs) was estimated, and risk factors for achalasia-related ECs were determined. Characteristics of ECs and treatment courses were also analyzed.

Results

Between 2010 and 2019, 2714 Japanese patients with achalasia and achalasia-related EMDs were recorded in 7 high-volume centers; 24 patients (21 men, 3 women) developed ECs. The incidence of ECs was estimated at 0.078 and 0.28 per 100 person-years from the onset and the diagnosis of disease, respectively. Kaplan–Meier estimate suggested that, in addition to a long history of achalasia, advanced age, male sex, and regular alcohol consumption were statistically significant risk factors for EC development. A prevalence of 40 ECs (12.5% multiple lesions, and 22.7% metachronal lesions) was also noted, predominantly distributed over the thoracic esophagus. All were histologically diagnosed as squamous cell carcinoma. Superficial ECs were successfully treated with endoscopic treatment in all cases, except one. Achalasia-related Barret esophagus was extremely rare, and Barret adenocarcinoma was not detected in our cohort.

Conclusion

The high relative risk of ECs was clarified in Japanese achalasia patients, although the absolute risk remained low. Therefore, surveillance endoscopy may be recommended in limited patients with several aforementioned risk factors determined. Superficial cancer can be treated with endoscopic treatment. Multiple and metachronal ECs should be screened.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Richter JE. Oesophageal motility disorders. Lancet. 2001;358:823–8.CrossRef Richter JE. Oesophageal motility disorders. Lancet. 2001;358:823–8.CrossRef
2.
Zurück zum Zitat Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet. 2014;383:83–93.CrossRef Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet. 2014;383:83–93.CrossRef
3.
Zurück zum Zitat Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. Gastroenterology. 2010;139:369–74.CrossRef Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. Gastroenterology. 2010;139:369–74.CrossRef
4.
Zurück zum Zitat Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol. 2005;100:1404–14.CrossRef Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol. 2005;100:1404–14.CrossRef
5.
Zurück zum Zitat Sato H, Takahashi K, Mizuno KI, et al. Esophageal motility disorders: new perspectives from high-resolution manometry and histopathology. J Gastroenterol. 2018;53:484–93.CrossRef Sato H, Takahashi K, Mizuno KI, et al. Esophageal motility disorders: new perspectives from high-resolution manometry and histopathology. J Gastroenterol. 2018;53:484–93.CrossRef
6.
Zurück zum Zitat Duffield JA, Hamer PW, Heddle R, et al. Incidence of achalasia in South Australia based on esophageal manometry findings. Clin Gastroenterol Hepatol. 2017;15:360–5.CrossRef Duffield JA, Hamer PW, Heddle R, et al. Incidence of achalasia in South Australia based on esophageal manometry findings. Clin Gastroenterol Hepatol. 2017;15:360–5.CrossRef
7.
Zurück zum Zitat Samo S, Carlson DA, Gregory DL, et al. Incidence and prevalence of achalasia in central Chicago, 2004–2014, since the widespread use of high-resolution manometry. Clin Gastroenterol Hepatol. 2017;15:366–73.CrossRef Samo S, Carlson DA, Gregory DL, et al. Incidence and prevalence of achalasia in central Chicago, 2004–2014, since the widespread use of high-resolution manometry. Clin Gastroenterol Hepatol. 2017;15:366–73.CrossRef
8.
Zurück zum Zitat Harvey PR, Thomas T, Chandan JS, et al. Incidence, morbidity and mortality of patients with achalasia in England: findings from a study of nationwide hospital and primary care data. Gut. 2019;68:790–5.CrossRef Harvey PR, Thomas T, Chandan JS, et al. Incidence, morbidity and mortality of patients with achalasia in England: findings from a study of nationwide hospital and primary care data. Gut. 2019;68:790–5.CrossRef
9.
Zurück zum Zitat van Hoeij FB, Ponds FA, Smout AJ, et al. (2018) Incidence and costs of achalasia in The Netherlands. Neurogastroenterol Motil 30. van Hoeij FB, Ponds FA, Smout AJ, et al. (2018) Incidence and costs of achalasia in The Netherlands. Neurogastroenterol Motil 30.
10.
Zurück zum Zitat Kim E, Lee H, Jung HK, et al. Achalasia in Korea: an epidemiologic study using a national healthcare database. J Korean Med Sci. 2014;29:576–80.CrossRef Kim E, Lee H, Jung HK, et al. Achalasia in Korea: an epidemiologic study using a national healthcare database. J Korean Med Sci. 2014;29:576–80.CrossRef
11.
Zurück zum Zitat Booy JD, Takata J, Tomlinson G, et al. The prevalence of autoimmune disease in patients with esophageal achalasia. Dis Esophagus. 2012;25:209–13.CrossRef Booy JD, Takata J, Tomlinson G, et al. The prevalence of autoimmune disease in patients with esophageal achalasia. Dis Esophagus. 2012;25:209–13.CrossRef
12.
Zurück zum Zitat Sato H, Yokomichi H, Takahashi K, et al. Epidemiological analysis of achalasia in Japan using a large-scale claims database. J Gastroenterol. 2019;54:621–7.CrossRef Sato H, Yokomichi H, Takahashi K, et al. Epidemiological analysis of achalasia in Japan using a large-scale claims database. J Gastroenterol. 2019;54:621–7.CrossRef
13.
Zurück zum Zitat Torres-Aguilera M, Remes Troche JM. Achalasia and esophageal cancer: risks and links. Clin Exp Gastroenterol. 2018;11:309–16.CrossRef Torres-Aguilera M, Remes Troche JM. Achalasia and esophageal cancer: risks and links. Clin Exp Gastroenterol. 2018;11:309–16.CrossRef
14.
Zurück zum Zitat Tustumi F, Bernardo WM, da Rocha JRM, et al. Esophageal achalasia: a risk factor for carcinoma. A systematic review and meta-analysis. Dis Esophagus. 2017;30:1–8.CrossRef Tustumi F, Bernardo WM, da Rocha JRM, et al. Esophageal achalasia: a risk factor for carcinoma. A systematic review and meta-analysis. Dis Esophagus. 2017;30:1–8.CrossRef
15.
Zurück zum Zitat Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 2013;108:1238–49.CrossRef Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 2013;108:1238–49.CrossRef
16.
Zurück zum Zitat Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63:570–80.CrossRef Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63:570–80.CrossRef
17.
Zurück zum Zitat Vaezi MF, Pandolfino JE, Yadlapati RH, et al. ACG clinical guidelines: diagnosis and management of achalasia. Am J Gastroenterol. 2020;115:1393–411.CrossRef Vaezi MF, Pandolfino JE, Yadlapati RH, et al. ACG clinical guidelines: diagnosis and management of achalasia. Am J Gastroenterol. 2020;115:1393–411.CrossRef
18.
Zurück zum Zitat Oude Nijhuis RAB, Zaninotto G, Roman S, et al. European guidelines on achalasia: United European Gastroenterology and European Society of Neurogastroenterology and motility recommendations. United Eur Gastroenterol J. 2020;8:13–33.CrossRef Oude Nijhuis RAB, Zaninotto G, Roman S, et al. European guidelines on achalasia: United European Gastroenterology and European Society of Neurogastroenterology and motility recommendations. United Eur Gastroenterol J. 2020;8:13–33.CrossRef
19.
Zurück zum Zitat Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27(2):160–74.CrossRef Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27(2):160–74.CrossRef
20.
Zurück zum Zitat Inoue H, Sato H, Ikeda H, et al. Per-oral endoscopic myotomy: a series of 500 patients. J Am Coll Surg. 2015;221:256–64.CrossRef Inoue H, Sato H, Ikeda H, et al. Per-oral endoscopic myotomy: a series of 500 patients. J Am Coll Surg. 2015;221:256–64.CrossRef
21.
Zurück zum Zitat Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med. 2014;371:836–45.CrossRef Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med. 2014;371:836–45.CrossRef
22.
Zurück zum Zitat The Japan Esophageal Society. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. 11th ed. Kanehara Co. Tokyo, Japan. The Japan Esophageal Society. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. 11th ed. Kanehara Co. Tokyo, Japan.
23.
Zurück zum Zitat Japan ES. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.CrossRef Japan ES. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.CrossRef
24.
Zurück zum Zitat Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6:119–30.CrossRef Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6:119–30.CrossRef
25.
Zurück zum Zitat Board WCoTE. WHO classification of tumours, 5th ed., Vol.1. 2019. Board WCoTE. WHO classification of tumours, 5th ed., Vol.1. 2019.
27.
Zurück zum Zitat Leeuwenburgh I, Scholten P, Alderliesten J, et al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol. 2010;105:2144–9.CrossRef Leeuwenburgh I, Scholten P, Alderliesten J, et al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol. 2010;105:2144–9.CrossRef
28.
Zurück zum Zitat Zendehdel K, Nyren O, Edberg A, et al. Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden. Am J Gastroenterol. 2011;106:57–61.CrossRef Zendehdel K, Nyren O, Edberg A, et al. Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden. Am J Gastroenterol. 2011;106:57–61.CrossRef
29.
Zurück zum Zitat Ohashi S, Miyamoto S, Kikuchi O, et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 2015;149:1700–15.CrossRef Ohashi S, Miyamoto S, Kikuchi O, et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 2015;149:1700–15.CrossRef
30.
Zurück zum Zitat Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–44.CrossRef Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–44.CrossRef
31.
Zurück zum Zitat Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–6.CrossRef Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–6.CrossRef
32.
Zurück zum Zitat Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009;24:729–35.CrossRef Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009;24:729–35.CrossRef
33.
Zurück zum Zitat Ichkhanian Y, Benias P, Khashab MA. Case of early Barrett cancer following peroral endoscopic myotomy. Gut. 2019;68:2107–10.CrossRef Ichkhanian Y, Benias P, Khashab MA. Case of early Barrett cancer following peroral endoscopic myotomy. Gut. 2019;68:2107–10.CrossRef
34.
Zurück zum Zitat Amano Y, Ishimura N, Furuta K, et al. Which landmark results in a more consistent diagnosis of Barrett’s esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc. 2006;64:206–11.CrossRef Amano Y, Ishimura N, Furuta K, et al. Which landmark results in a more consistent diagnosis of Barrett’s esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc. 2006;64:206–11.CrossRef
35.
Zurück zum Zitat Amano Y, Kinoshita Y. Barrett esophagus: perspectives on its diagnosis and management in asian populations. Gastroenterol Hepatol. 2008;4:45–53. Amano Y, Kinoshita Y. Barrett esophagus: perspectives on its diagnosis and management in asian populations. Gastroenterol Hepatol. 2008;4:45–53.
36.
Zurück zum Zitat Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v50–7.CrossRef Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v50–7.CrossRef
37.
Zurück zum Zitat Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus. 2019;16:221–45.CrossRef Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus. 2019;16:221–45.CrossRef
38.
Zurück zum Zitat Ponds FA, Moonen A, Smout A, et al. Screening for dysplasia with Lugol chromoendoscopy in longstanding idiopathic achalasia. Am J Gastroenterol. 2018;113:855–62.CrossRef Ponds FA, Moonen A, Smout A, et al. Screening for dysplasia with Lugol chromoendoscopy in longstanding idiopathic achalasia. Am J Gastroenterol. 2018;113:855–62.CrossRef
39.
Zurück zum Zitat Markar SR, Wiggins T, MacKenzie H, et al. (2019) Incidence and risk factors for esophageal cancer following achalasia treatment: national population-based case-control study. Dis Esophagus 32. Markar SR, Wiggins T, MacKenzie H, et al. (2019) Incidence and risk factors for esophageal cancer following achalasia treatment: national population-based case-control study. Dis Esophagus 32.
Metadaten
Titel
Achalasia and esophageal cancer: a large database analysis in Japan
verfasst von
Hiroki Sato
Shuji Terai
Yuto Shimamura
Shinwa Tanaka
Hironari Shiwaku
Hitomi Minami
Chiaki Sato
Ryo Ogawa
Hiroshi Yokomichi
Haruhiro Inoue
Publikationsdatum
04.02.2021
Verlag
Springer Singapore
Erschienen in
Journal of Gastroenterology / Ausgabe 4/2021
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-021-01763-6

Weitere Artikel der Ausgabe 4/2021

Journal of Gastroenterology 4/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.